<DOC>
	<DOCNO>NCT02789254</DOCNO>
	<brief_summary>This first human , prospective , monocentric , nonrandomized , open-label study investigate safety , tolerability , preliminary efficacy , pharmacokinetics , pharmacodynamics immunogenicity Fc-optimized antibody FLYSYN monotherapy adult subject .</brief_summary>
	<brief_title>FLYSYN MRD Positive AML</brief_title>
	<detailed_description>Cohort 1 : Patient 1-3 : FLYSYN 0.5 mg/m² body surface area ( BSA ) day 1 Cohort 2 : Patient 4-6 : FLYSYN 0.5 mg/m² body surface area ( BSA ) day 1 FLYSYN 1.0 mg/m² BSA day 2 Cohort 3 : Patient 7-9 : FLYSYN 0.5 mg/m² body surface area ( BSA ) day 1 , FLYSYN 4.5 mg/m² BSA day 2 Cohort 4 : Patient 10-12 13-28 : FLYSYN 0.5 mg/m² body surface area ( BSA ) day 1 , FLYSYN 14.5 mg/m² BSA day 2</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Age ≥18 year time voluntarily sign IECapproved informed consent , upper age limit Diagnosis AML NPM1 mutation accord WHO criteria Confirmed FLT3 expression leukemic cell Known mutational status FLT3 ( FLT3ITD , FLT3TKD , FLT3 wild type ) Hematological CR ( ANC count &gt; 1.000/μL , Thrombocytes &gt; 100.000/μL ) , MRD positivity therapy except allogeneic stem cell transplantation Life expectancy &gt; 3 month ECOG performance status ≤ 2 Subject must willing receive transfusion blood product Be willing able comply study protocol duration study Females childbearing potential ( FCBP ) must undergo repetitive pregnancy test ( serum urine ) result must negative Reliable contraception maintain throughout study 6 month study treatment Unless practice complete abstinence heterosexual intercourse , sexually active FCBP must agree use adequate contraceptive method Males ( include vasectomy ) must use effective barrier method contraception throughout study 6 month study treatment sexually active female childbearing potential All subject must : understand investigational product could potential teratogenic risk . counseled pregnancy precaution risk fetal exposure . able comply studyrelated procedure , medication use , evaluation . The presence ANY follow criterion exclude patient study enrollment : Patients proceed hematopoietic stem cell transplantation ( suitable candidate donor available , informed consent patient ) Pregnant breast feeding female &gt; 5 % blast bone marrow extramedullary disease Positivity HAMA/HAHA know immunoglobulin intolerance Known positivity HIV , active HBV , HCV , Hepatitis A infection No consent registration , storage process individual diseasecharacteristics course well information family physician and/or physician involve treatment study participation No consent biobanking Presence medical/psychiatric condition laboratory abnormality may limit full compliance study , increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator , would make patient inappropriate entry study Prior history malignancy , AML/myelodysplastic syndrome ( MDS ) , unless subject ( ) free disease ≥ 2 year . ( ii ) Exceptions include follow : Basal cell carcinoma skin , carcinoma situ cervix , carcinoma situ breast , incidental histological finding prostate cancer ( TNM stage T1a T1b ) Patients receive medication list Appendix IV `` Prohibited Medications '' ( within 14 day prior first dose study drug ) Uncontrolled infection , e.g . infection progress adequate antimicrobial/antifungal/antiviral treatment Patients ongoing treatment another investigational medication treat investigational medication within 14 day screen Current treatment immunosuppressive agent Systemic disease ( cardiovascular , renal , hepatic , etc . ) would prevent study treatment ( e.g. , creatinine &gt; 1.5x upper normal serum level ; bilirubin , AST AP &gt; 2.5x upper normal serum level ; heart failure NYHA III/IV ; severe obstructive restrictive ventilation disorder )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>Fms-like receptor tyrosine kinase ( FLT3 )</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>complete remission</keyword>
	<keyword>CD135</keyword>
	<keyword>antibody</keyword>
	<keyword>Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Fc-optimized</keyword>
</DOC>